Title

Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.

Document Type

Journal Article

Publication Date

3-1-2018

Journal

Journal of the European Academy of Dermatology and Venereology : JEADV

Volume

32

Issue

3

DOI

10.1111/jdv.14738

Keywords

Adult; Anti-Inflammatory Agents, Non-Steroidal; Drug Administration Schedule; Etanercept; Female; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Placebos; Psoriasis; Quality of Life; Severity of Illness Index; Thalidomide

Peer Reviewed

1

This document is currently not available here.

Share

COinS